Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Genmab A/S

GMAB ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Large Cap Analyst: BUY

Last Close

$33.02

▼ -1.29%

Market Cap $20.59B · Vol 892.38K

Key Metrics

P/E Ratio

26.02

FWD: 21.13

Market Cap

$20.59B

Large Cap

Div Yield

0.00%

N/A

EPS Growth

-31.60%

YoY

RSI (14)

77.70

Momentum

Beta

0.84

vs Market

52W High

$35.43

6.80% below

52W Low

$23.62

39.80% above

Volume

892.38K

Avg 797.27K

P/B

3.25

Price-to-book

ROE

17.60%

Return on equity

Free Float

100.00%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Genmab A/S (GMAB) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GMAB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.55%

+14.37%

+22.89%

+12.31%

YTD

+7.21%

+33.96%

-11.78%

-30.12%

Financials & Valuation

TTM · Annual

Total Revenue	$3.72B
Net Income	$963.00M
Revenue Growth (YoY)	+24.86%
Gross Margin	93.60%
Operating Margin	34.09%
Net Profit Margin	25.89%
ROE	17.60%
ROA · ROIC	12.49% · 11.90%

P/E Ratio	26.02
Forward P/E (FY1)	21.13
PEG Ratio	-1.62
P/S	5.19
P/B	3.25
P/FCF	17.07
EPS Growth	-31.60%
Outstanding Shares	62.38M

Technical Indicators

50-Day SMA	$28.91
200-Day SMA	$29.16
RSI (14)	77.70
Beta	0.84
52-Week High	$35.43
52-Week Low	$23.62

Volume Today	892.38K
Avg Daily Volume (30D)	797.27K
Relative Volume	1.12x
Volatility (10D)	26.50
Volatility (30D)	25.54
Free Float	100.00%

Analyst Consensus

BUY

Current Price $33.02

Mean Target $39.79

52W Low$23.62 52W High$35.43

Current

Target

$23.62 $35.43

Current Analyst target

+20.49% upside potential · 13 analysts

Identifiers

ExchangeNasdaq

FIGIBBG004MPKMY3

ISINUS3723032062

CountryDenmark

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 6, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -3.94% ARGX.BR argenx SE -4.19% ARGX argenx SE -2.76% INSM Insmed Inc -1.42% 2269.HK WuXi Biologics (Cayman) Inc -4.71%

Company Profile

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.